BACKGROUND: Mutations in KCNJ2, the gene encoding the human inward rectifier potassium channel Kir2.1 (IK1 or IKir2.1), have been identified in Andersen-Tawil syndrome. Andersen-Tawil syndrome is a multisystem inherited disease exhibiting periodic paralysis, cardiac arrhythmias, and dysmorphic features at times mimicking catecholaminergic polymorphic ventricular tachycardia. METHODS AND RESULTS: Our proband displayed dysmorphic features including micrognathia, clinodactyly, and syndactyly and exhibited multiform extrasystoles and bidirectional ventricular tachycardia both at rest and during exercise testing. The patient's symptoms continued after administration of nadolol but subsided after treatment with flecainide. Molecular genetic screening revealed a novel heterozygous mutation (c.779G>C/p.R260P) in KCNJ2. Whole-cell patch-clamp studies conducted in TSA201 cells transfected with wild-type human KCNJ2 cDNA (WT-KCNJ2) yielded robust IKir2.1 but no measurable current in cells expressing the R260P mutant. Coexpression of WT and R260P-KCNJ2 (heterozygous expression) yielded a markedly reduced inward IKir2.1 compared with WT alone (-36.5±9.8 pA/pF versus -143.5±11.4 pA/pF, n=8 for both, P<0.001, respectively, at -90 mV), indicating a strong dominant negative effect of the mutant. The outward component of IKir2.1 measured at -50 mV was also markedly reduced with the heterozygous expression versus WT (0.52±5.5 pA/pF versus 23.4±6.7 pA/pF, n=8 for both, P<0.001, respectively). Immunocytochemical analysis indicates that impaired trafficking of R260P-KCNJ2 channels. CONCLUSIONS: We report a novel de novo KCNJ2 mutation associated with classic phenotypic features of Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. The R260P mutation produces a strong dominant negative effect leading to marked suppression of IK1 secondary to a trafficking defect.
BACKGROUND: Mutations in KCNJ2, the gene encoding the human inward rectifier potassium channel Kir2.1 (IK1 or IKir2.1), have been identified in Andersen-Tawil syndrome. Andersen-Tawil syndrome is a multisystem inherited disease exhibiting periodic paralysis, cardiac arrhythmias, and dysmorphic features at times mimicking catecholaminergic polymorphic ventricular tachycardia. METHODS AND RESULTS: Our proband displayed dysmorphic features including micrognathia, clinodactyly, and syndactyly and exhibited multiform extrasystoles and bidirectional ventricular tachycardia both at rest and during exercise testing. The patient's symptoms continued after administration of nadolol but subsided after treatment with flecainide. Molecular genetic screening revealed a novel heterozygous mutation (c.779G>C/p.R260P) in KCNJ2. Whole-cell patch-clamp studies conducted in TSA201 cells transfected with wild-type humanKCNJ2 cDNA (WT-KCNJ2) yielded robust IKir2.1 but no measurable current in cells expressing the R260P mutant. Coexpression of WT and R260P-KCNJ2 (heterozygous expression) yielded a markedly reduced inward IKir2.1 compared with WT alone (-36.5±9.8 pA/pF versus -143.5±11.4 pA/pF, n=8 for both, P<0.001, respectively, at -90 mV), indicating a strong dominant negative effect of the mutant. The outward component of IKir2.1 measured at -50 mV was also markedly reduced with the heterozygous expression versus WT (0.52±5.5 pA/pF versus 23.4±6.7 pA/pF, n=8 for both, P<0.001, respectively). Immunocytochemical analysis indicates that impaired trafficking of R260P-KCNJ2 channels. CONCLUSIONS: We report a novel de novo KCNJ2 mutation associated with classic phenotypic features of Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry. The R260P mutation produces a strong dominant negative effect leading to marked suppression of IK1 secondary to a trafficking defect.
Authors: N M Plaster; R Tawil; M Tristani-Firouzi; S Canún; S Bendahhou; A Tsunoda; M R Donaldson; S T Iannaccone; E Brunt; R Barohn; J Clark; F Deymeer; A L George; F A Fish; A Hahn; A Nitu; C Ozdemir; P Serdaroglu; S H Subramony; G Wolfe; Y H Fu; L J Ptácek Journal: Cell Date: 2001-05-18 Impact factor: 41.582
Authors: M R Donaldson; J L Jensen; M Tristani-Firouzi; R Tawil; S Bendahhou; W A Suarez; A M Cobo; J J Poza; E Behr; J Wagstaff; P Szepetowski; S Pereira; T Mozaffar; D M Escolar; Y-H Fu; L J Ptácek Journal: Neurology Date: 2003-06-10 Impact factor: 9.910
Authors: Ricardo Caballero; Pablo Dolz-Gaitón; Ricardo Gómez; Irene Amorós; Adriana Barana; Marta González de la Fuente; Lourdes Osuna; Juan Duarte; Angelica López-Izquierdo; Ignacio Moraleda; Enrique Gálvez; José Antonio Sánchez-Chapula; Juan Tamargo; Eva Delpón Journal: Proc Natl Acad Sci U S A Date: 2010-08-16 Impact factor: 11.205
Authors: Martin Tristani-Firouzi; Judy L Jensen; Matthew R Donaldson; Valeria Sansone; Giovanni Meola; Angelika Hahn; Said Bendahhou; Hubert Kwiecinski; Anna Fidzianska; Nikki Plaster; Ying-Hui Fu; Louis J Ptacek; Rabi Tawil Journal: J Clin Invest Date: 2002-08 Impact factor: 14.808
Authors: Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann Journal: J Mol Cell Cardiol Date: 2009-10-14 Impact factor: 5.000
Authors: Matthew M Kalscheur; Ravi Vaidyanathan; Kate M Orland; Sara Abozeid; Nicholas Fabry; Kathleen R Maginot; Craig T January; Jonathan C Makielski; Lee L Eckhardt Journal: Heart Rhythm Date: 2014-02-21 Impact factor: 6.343
Authors: Oscar Campuzano; Catarina Allegue; Sara Partemi; Anna Iglesias; Antonio Oliva; Ramon Brugada Journal: Int J Legal Med Date: 2014-02-16 Impact factor: 2.686
Authors: Louise Reilly; Francisco J Alvarado; Di Lang; Sara Abozeid; Hannah Van Ert; Cordell Spellman; Jarrett Warden; Jonathan C Makielski; Alexey V Glukhov; Lee L Eckhardt Journal: Circ Arrhythm Electrophysiol Date: 2020-08-04
Authors: Abdullah Omar; Mi Zhou; Adam Berman; Robert A Sorrentino; Neela Yar; Neal L Weintraub; Il-Man Kim; Wei Lei; Yaoliang Tang Journal: Expert Rev Precis Med Drug Dev Date: 2016-12-02